Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Sell NTPC, Adani Port, Tata Steel; buy Cipla: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may buy Cipla with a target of Rs 377 and sell Tata Steel with a target of Rs 359.

    • Buy Cipla, Lupin: Gopi Suvanam

      Gopi Suvanam, Founder of InvestWorks advises investing in Lupin with a target of around Rs 1,150.

    • Buy Cipla; sell Bharti Airtel: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Cipla and sell Bharti Airtel.

    • Prefer Glenmark Pharma, Cipla: Deven Choksey

      Deven Choksey, MD of KR Choksey Shares & Securities prefers Glenmark Pharma and Cipla within the pharma space.

    • Prefer pharma, IT services space: Bhuvnesh Singh

      Bhuvnesh Singh, MD & Head of India Research at Barclays prefer pharma and IT services space.

    • Gopi Suvanam bullish on pharma space

      Gopi Suvanam, founderof InvestWorks has a bullish stance on pharma space including Cipla and Lupin.

    • 6 stocks likely to see lot of action today

      Shrikant Chouhan of Kotak Securities advises selling Reliance Industries with a target of Rs 780-790 and buying Lupin with a target of Rs 960-970.

    • Cipla may touch Rs 465-470: Abhishek Karande

      Abhishek Karande of SBICAP Securities feels that Cipla may touch Rs 465-470.

    • Go long in Cipla: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker recommends going long in Cipla as the stock may move towards Rs 445-450.

    • Buy Cipla on decline: Shardul Kulkarni

      Shardul Kulkarni of Angel Broking recommends buying Cipla on decline at around Rs 408-410 as the stock may test Rs 430-435.

    • See higher levels in Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may see higher levels in Cipla.

    • 6 stocks that should do well today

      Shrikant Chouhan of Kotak Securities suggests buying Cipla with a target of Rs 420-425 and Federal Bank with a target of Rs 85.50-87.

    • Cipla looks attractive, says Gopi Suvanam

      According to Gopi Suvanam, Founder of InvestWorks, Cipla is looking attractive at this level.

    • Buy Lupin, Cipla, Dr Reddys Lab: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Lupin, Divis Laboratories, Sun Pharmaceutical Industries, Cipla and Dr Reddys Laboratories.

    • Pharma space to outperform, says Jaideep Goswami

      According to Jaideep Goswami, Head of Equity at ICICI Securities, pharma sector being export oriented sector will continue to outperform in at least first few months of the year.

    • Avoid Ranbaxy, Sun Pharma: Gopi Suvanam

      According to Gopi Suvanam of Investworks, one may avoid Ranbaxy Laboratories and Sun Pharmaceutical Industries.

    • Cipla may add 10%, says Gopi Suvanam

      Gopi Suvanam, Founder at InvestWorks feels that Cipla may gain 10 percent.

    • Cipla may touch Rs 445-465: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that Cipla may touch Rs 445-465 in next one year.

    • Buy Cipla, Divis Laboratories: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may buy Cipla and Divis Laboratories.

    • Sell Cipla, buy Dabur India: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Dabur India from FMCG pack. However, he advises selling Cipla.

    • Prefer Divis Labs, Ranbaxy, Maruti: Abhishek Karande

      Abhishek Karande of SBICAP Securities is of the view that one may prefer Cipla, Divi‘s Laboartories, Ranbaxy Laboratories within the pharmaceutical sector, and Maruti Suzuki India and Hero Motocorp within the automobile space.

    • Buy Cipla, may touch Rs 425: Pritesh Mehta

      According to Pritesh Mehta of IIFL, one may buy Cipla as the stock may touch Rs 425.

    • Pick Cipla, Dr Reddys Labs: Sriram Rathi

      Sriram Rathi, pharma analyst at Anand Rathi is of the view that one may pick Cipla and Dr Reddys Laboratories from largecap pharma space.

    • Buy Cipla on correction, says Abhishek Karande

      Abhishek Karande of SBICap Securities recommends buying Cipla on correction as the stock may touch Rs 440.

    • USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

      The USFDA today approved Ranbaxy‘s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347